Showing 2471-2480 of 3039 results for "".
- Heidelberg Engineering and AI Software Partners Present Workflow Solution for Ophthalmic Analytics at EURETINA and ESCRShttps://modernod.com/news/heidelberg-engineering-and-ai-software-partners-present-secure-workflow-solution-for-ophthalmic-analytics-at-euretina-and-escrs/2481050/Heidelberg Engineering is expanding its healthcare IT portfolio with the introduction of Heidelberg AppWay. This latest addition to the company’s ecosystem offers secure access to ophthalmic software analytics and AI-powered support systems, according to Heidelberg. It will be embedded into
- Alcon to Acquire Aerie Pharmaceuticalshttps://modernod.com/news/alcon-to-acquire-aerie-pharmaceuticals/2481041/In another move to bolster its glaucoma portolio and expand its pharmaceutical offerings, Alcon announced it is acquiring Aerie Pharmaceuticals for about $770 million, or $15.25 per share—a premium of 37% to Aerie’s lastest closing price. The transaction was a
- Opthea Announces Financing Deals for OPT-302 in Wet AMDhttps://modernod.com/news/opthea-announces-financing-deals-for-opt-302-in-wet-amd/2481027/Opthea announced two financing deals aimed at advancing OPT-302, a drug candidate for wet age-related macular degeneration (AMD). Opthea announced a nondilutive financing transaction for up to $170 million from investment funds working with Launch Therapeutics to finance and advance the
- ProQR to Focus Exclusively on Axiomer RNA-Editing Technology and Partner Ophthalmology Programshttps://modernod.com/news/proqr-to-focus-exclusively-on-axiomer-rna-editing-technology-and-partner-ophthalmology-programs/2481023/ProQR Therapeutics provided an update on its ophthalmology programs following feedback from the European Medicines Agency (EMA) related to sepofarsen and will now focus exclusively on its Axiomer RNA-editing technology platform
- OcuTerra Therapeutics Announces First Patient Dosed in OTT166 Phase 2 DR:EAM Clinical Trial for Diabetic Retinopathyhttps://modernod.com/news/ocuterra-therapeutics-announces-first-patient-dosed-in-ott166-phase-2-dream-clinical-trial-for-diabetic-retinopathy/2481009/OcuTerra Therapeutics announced that the first patient was dosed in its phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) clinical trial evaluating OTT166 in adult patients with moderately severe to severe nonproliferative diabetic retinopathy (NPDR) or mild proli
- High-Tech Imaging Offers New Way to Detect Signs of Early Glaucomahttps://modernod.com/news/high-tech-imaging-offers-new-way-to-detect-signs-of-early-glaucoma/2481008/A new, noninvasive ocular imaging method may be able to detect an early indicator of glaucoma in time to prevent disease progression and vision loss, according to a new study from New York Eye and Ear Infirmary of Mount Sinai (NYEE). The study was published in the July/August issue of Op
- New App Designed to Use Artificial Intelligence to Reduce Digital Eye Strainhttps://modernod.com/news/new-app-designed-to-use-artificial-intelligence-to-reduce-digital-eye-strain/2481004/Robin Kuriakose, MD, a fellow physician in cornea and refractive surgery at the Northwestern Memorial Hospital, has launched SightKick, a new MacOS application designed to reduce digital eye strain: SightKick. Digital eye strain is a gr
- Yuyu Pharma Announces First Patient Enrolled in Phase 2 Study of YP-P10 Ophthalmic Solution for the Treatment of Dry Eye Diseasehttps://modernod.com/news/yuyu-pharma-announces-first-patient-enrolled-in-phase-2-clinical-study-evaluating-yp-p10-ophthalmic-solution-for-the-treatment-of-dry-eye-disease/2480996/Yuyu Pharma announced the enrollment of the first patient in a phase 2 clinical study evaluating YP-P10, a novel and patented synthetic peptide with anti-inflammatory and wound healing properties being investigated to treat patients with dry eye disease (DED). Yuyu received cl
- AcuFocus Receives FDA Approval for the IC-8 Apthera IOL, the First and Only Small Aperture Lenshttps://modernod.com/news/acufocus-announces-fda-approval-for-the-ic-8-apthera-iol-the-first-and-only-small-aperture-lens-for-cataract-surgery/2480986/AcuFocus has received FDA approval for its IC-8 Apthera IOL, the first and only non-toric extended depth-of-focus IOL approved for the 82% of cataract patients who have as much as 1.5 diopters (D) of corneal astigmatism.2 “We are delighted to receive
- Second Sight Medical Products Announces Year 4 NIH Funding of its Orion Studyhttps://modernod.com/news/second-sight-medical-products-announces-year-4-nih-funding-of-its-orion-study/2480982/Second Sight Medical Products announced that the company received notice from the National Institutes of Health (NIH) of the release of year 4 funding for its Early Feasibility Clinical Trial of a Visual Cortical Prosthesis (Orion Trial), grant 5UH3NS103442. The NIH released&n